1、 16.53 2.29。“”。、。“+”“”“”PBL、“”8、。、。、“”。1.M.2015 11-12.2.J.2019 41 4 307-309.3.J.2020 34 4 25-27.4.J.2019 11 2 32-34.5.J.2019 37 9 57-58.6.J.2018 32 5 22-23.7.J.2019 33 5 38-40.8.J.2017 19 1 62-65.1 1 1 2 2 1*1.2.364000。2019 2021。、DDDs、DDC B/A。2019 2021、DDDs。3、3、2020、2021 65.84%、49%56.16%、69.36%。969.
2、4 A 1006-3765 2023-04-0062-05。2019LYF12008 Dy n a m ic An a ly s is o f An tin e o p la s tic Dr u g s Pa s s in g Na tio n a l Me d ic a l I n s u r-a n c e Ne g o tia tio n CHE N Ch u n-m e i 1 LI N We n-h o n g 1 Z HAO Z h i-b in 1 CHE N Do n g-fe n g 2 Z HAN-p e n g 2 AO Me i 1*1.De p a r tm e n
3、 t o f Ph a r m a c y Lo n g y a n Fir s t Ho s p ita l Affilia te d o f Fu jia n Me d ic a l U n iv e r s ity Lo n g y a n 364000 Ch in a 2.De p a r tm e n t o f Or th o p e d ic s Lo n g y a n Fir s t Ho s p ita l Affilia te d o f Fu jia n Me d ic a l U n iv e r s ity Lo n g y a n 364000 Ch in a 2
4、 6 2023 35 4 AB ST ACT O BJ ECT I V E I nv esti gati ng the cl i ni calappl i cati on si tu ati on andchangi ng trendofnati onalnegoti a-ti on anti neopl asti c dru gs i n ou r hospi talaf ter the i mpl ementati on ofrel ev antpol i ci es i nsu rance negoti ati on so as toprov i deref erencef or the
5、opti mi z ati on andadj u stmentofhospi taldru gl i st.M ET HO DS Thedataofnati onalnegoti a-ti on anti neopl asti c dru gs f rom 2019 to 2021 w ere col l ected.The v ari ety sal es amou nt DDDs dai l y av erage cost DDC andthe sorti ng rati o B/A w ere anal y z ed.ES U L T S I n the y ear of2019 to
6、 2021 the v ari eti es sal esamou ntandDDDs ofnati onalnegoti ati on anti neopl asti cdru gs show edan i ncreasi ngtrendy ear by y ear andthetrastu-z u mabw as the f i rsti n sal es amou nt DDDs f or three consecu ti v e y ears.The nati onalnegoti ati on anti neopl asti c dru gsw ere mai nl y u sedf
7、 or breastcancer gastroi ntesti naltu mor andl u ngcancer.Thetop threeanti neopl asti cdru gs i n termsofcost w ere trastu z u mab bev aci z u mab and oci ti ni b w i th good sy nchroni z ati on of dru g consu mpti on DDDs andDDC.I n 2020and2021 sal es amou nti ncreasedby 65.84%and49%anddru g f requ
8、 ency i ncreasedby 56.16%and69.36%respecti v el y.CO N CL U S I O N The nati onalheal th i nsu rance negoti ati on pol i cy promotthe u se ofan-ti neopl asti cdru gs i mprov etheaccessi bi l i ty ofthesedru gs to pati ents andal so l eadthesu bstanti ali ncreasi ngofdru gcosts i n hospi tal.The cu r
9、rentsi tu ati on andtendency ofanti neopl asti c dru gs u se i n ou r hospi talare basi cal l y i n l i new i th the generaltrendofdru gs consu mpti on.KE Y WO DS A nti neopl asti cdru gs Nati onalmedi cali nsu rancenegoti ati ons Dru gf requ ency Dru gamou nt2018 10 17 1、17 2。2018 11 29。2019 2021。1
10、 1.1 H I S 2019 2021、。1.2 WH O def i ned dai l y doses DDDs、def i neddai l y cost DDC。def i neddai-l y does DDD。DDD WH O A TC 3、18 4。DDDs=/DDD DDDs。DDC=/DDDs。DDDs A B B/A 1 1 1。2 2.1 2019 2021、2019 2021 40 44 31 78%。1 2019 2021 56.16%69.36%65.84%、48.88%。1 2019 2021、2019 2020 2020%2021 2021%17 29 70.
11、59 39 34.48 1476.88 2449.24 65.84 3646.39 48.88DDDs 50827.20 79369.46 56.16 134417.64 69.362.2 2019 2021 2019 2021 2。77.50%。、3。、。2.3 DDDs 2019 2021 3 6 Strai tPharmaceu ti calJou rnalV ol.35 No.4 2023DDDs 2。、DDDs DDDs。、DDDs DDDs。2.4 DDC B/A 2019 2021 DDC B/A 2。、4 DDC B/A 1。2019 B/A 2 2020 B/A 2 2021
12、 3 B/A 2、。B/A 1。2 2019 2021、DDDs、DDC B/A 2019 2020 2021 BDDDs ADDC B/A BDDDs ADDC B/A BDDDs ADDC B/A 0.44g 503.25 1 23485 1 214 1 503.80 1 23510.67 1 214 1 614.35 1 28669.67 1 214 1 0.1g 251.25 2 7816.67 2 321 1 299.85 2 9328.67 3 321 0.67 429.30 2 13356 5 321 0.4 15mg 200.36 3 7666.88 3 261 1 146.5
13、6 6 5608.13 4 261 1.5 208.15 6 7965 6 261 1 0.25g 104.33 4 2.28 15 457600 0.27 174.35 5 3.75 27 464921 0.19 172.97 8 3.78 37 457600 0.22 80mg 73.66 5 3960 4 186 1.25 287.37 3 15390 2 186 1.5 357.68 4 19230 3 186 1.33 0.1g 60.22 6 0.88 17 688200 0.35 197.15 4 2.86 28 688200 0.14 233.16 5 3.39 38 6882
14、00 0.13 12mg 59.29 7 2898 5 204 1.4 38.88 13 1900.5 8 204 1.63 30.29 22 1480.5 14 204 1.57 8mg 59.29 7 2898 6 204 1.33-0.31 40 21 35 149 1.14 0.2g 54.50 9 1.47 16 370720 0.56 75.63 10 2.04 29 370720 0.34 60.06 14 1.62 41 370720 0.34 40mg 47.33 10 914.67 7 517 1.43 89.83 9 1736 9 517 1 36.22 19 700 2
15、1 517 0.9 0.14g 28.90 11 570 8 507 1.38 117.12 8 2310 7 507 1.14 94.30 11 1860 12 507 0.92 0.24g 14.57 12 0.2 18 717520 0.67 4.52 27 0.06 31 717520 0.87 2.51 37 0.04 42 717520 0.88 0.25g 6.21 13 108 12 575 1.08 13.00 22 226 19 575 1.16 8.40 32 146 31 575 1.03 50mg 5.45 14 133 11 410 1.27 33.29 16 81
16、2 14 410 1.14 106.76 9 2604 8 410 1.13 100mg 4.46 15 156.67 10 284 1.5 47.19 12 1656.67 10 284 1.2 21.46 25 753.33 19 284 1.32 4mg 1.48 16 28 14 528 1.14 31.08 17 588 15 528 1.13 56.24 16 1064 18 528 0.89 2mg 1.20 17 157.5 9 76 1.89 1.61 30 210 22 76 1.36 5.08 33 665 22 76 1.5 0.2g 1.14 18 30 13 380
17、 1.38 7.41 24 195 23 380 1.04 24.51 24 645 23 380 1.04 420mg-128.33 7 5439 6 235 1.17 377.57 3 16002 4 235 0.75 150mg-73.11 11 1344 11 544 1 198.02 7 3640 7 544 1 150mg-38.76 14 950 12 408 1.17 16.32 27 400 25 408 1.08 150mg-35.99 15 882 13 408 1.15 103.96 10 2548 9 408 1.11 80mg-24.08 18 5600 5 43
18、3.6 88.13 12 20496 2 43 6 0.15g-22.31 19 0.56 30 396587 0.63 69.60 13 1.76 40 396587 0.325 5mg-13.77 20 350 17 393 1.18 53.96 18 1372 15 393 1.2 10mg-13.44 21 45.5 25 533 0.84-5mg-10.58 23 280 18 378 1.28 27.25 23 721 20 378 1.15 1mg-6.55 25 138.6 24 472 1.04 2.58 36 54.6 34 472 1.06 5mg-5.90 26 383
19、.46 16 153 1.63 16.65 26 1082.71 17 153 1.53 40mg-4.48 28 224 20 200 1.4 11.48 29 574 24 200 1.21 0.2g-2.43 29 210 21 640 1.38-3750i u-0.89 31 42 26 212 1.19 4.17 34 196 28 212 1.21 80mg-59.56 15 1504 13 396 1.15 0.2g-54.02 17 2.77 39 195000 0.44 4mg-32.72 20 1212 16 270 1.25 0.2g-31.33 21 2247 10 1
20、39 2.1 4 6 2023 35 4 2 2019 2020 2021 BDDDs ADDC B/A BDDDs ADDC B/A BDDDs ADDC B/A 10.8mg-11.49 28 2205 11 52 2.55 100mg-10.20 30 170 30 600 1 55mg-9.50 31 270 26 352 1.19 5mg-3.29 35 224 27 147 1.3 40mg-1.56 38 56 33 278 1.15 80mg-1.09 39 74.67 32 145 1.22 150mg-0.11 41 14 36 81 1.14 60mg-0.06 42 1
21、81.82 29 3 1.45 250mg/m2 1 2mg/kg 1 420mg 1 3 7.5 mg/kg 1 3 7.5 mg/m2 1 14 3 100mg 1 200mg 1 3.6 mg 1 4 1 1 14 d 7 d 4 mg 1 8 15 4 75 mg/m2 7 d 4 160mg 1 21 d 7 d 3 mg/m2 1 3 30mg 2 2500I U/m2 1 2 3 mg kg 1 1 2 50mg 1 4 2。3。3、。2 H er2 H er2 H er2。H er2 H er2 H er2 5。H er2。H er2 6。DDDs B/A 1、DDC。H er2 H er1-H er2 H er2-H er3 H er2 7。H er2 6。-E G F-TKI E G F、H er2。8。2 DDDs B/A 3。V E G F/V E G F、E G F。V E G F V E G F 9。mC C、NCCN。mC C OS PFS。DDDs B/A 2021 B/A 0.4、DDC。E G F mC C E G-F、10 11。A S/B A F。B/A 0.5。-V E G F-TKI。、5 6 Strai tPharmaceu ti calJou rnalV ol.35 No.4 2023
